Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Legal

Deals. Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion

Deals. Jazz Pharma to Buy Cannabinoid-Drug Maker for $7.2 Billion

Terms represent 50% premium for U.K.-based GW Pharmaceuticals. GW’s Epidiolex was first cannabis-derived drug cleared by FDA. (Bloomberg, USA, 03.02.2021)

https://www.bloomberg.com/news/articles/2021-02-03/jazz-pharmaceuticals-to-buy-gw-for-7-2-billion-in-cash-stock